Bell, Brendan

Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. de microbiologie et infectiologie

Coordonnées

Courriel


819-821-8000, poste 75327

Diplômes

(1997) Doctorate (Doctor of Philosophy). University of British Columbia.

(1990) Bachelor's (Bachelor of Science, Honours). McGill University.

(1988) Bachelor's (Bachelor of Science). University of Alberta.

Présentation

Sujets de recherche

Gene Regulation and Expression, Apoptosis, Cell Signaling, AIDS / HIV.

Disciplines de recherche

Molecular Biology, Biochemistry, Virology.

Mots-clés

Alternative splicing, Apoptosis, Biochemistry, Genomics, HIV, Molecular oncology, Signal transduction, Transcription, Tumor suppressors.

Intérêts de recherche

Le professeur Bell étudie deux maladies dévastatrices: le cancer et le VIH/SIDA. Pour mieux comprendre et donc mieuxtraiter ces maladies son équipe emploie des approches expérimentalesmultidisciplinaires incluant la biologie moléculaire, la biologie cellulaire, la génomique et la protéomique. TAF6? est un facteur de transcription qui induit la mort cellulaire de multiples types de cancer. Nous étudions les mécanismes moléculaires par lesquels TAF6? tue les cellules cancéreuses avec unaccent sur le cancer du sein, le cancer du poumon et le cancer du colon. TAF6? émerge comme une nouvelle cible potentielle anti-tumorale. Dans la lutte contre le VIH/SIDA nous étudions l’obstacle majeur à la guérison, la latence virale. Nous avons découvert une nouvelle famille de facteurs de transcription régissant lalatence du VIH. Afin d’éradiquer le VIH latent nous étudions leur implication dans la capacité du VIH à «se cacher» du système immunitaire ainsi que les antiviraux existants.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français, Espagnol (castillan)

Prix et distinctions

  • (2013) CBC/Radio-Canada - La Presse Personality of the year in Science. Radio-Canada (CBC) / La Presse. (Prize / Award).
  • (2009) Canada Research Chair in Genomic regulation. Canada Research Chairs. (Distinction).
  • (2004) Marie Curie Postdoctoral Fellowship. European community. (Distinction).
  • (2002) INSERM Poste Vert. Institut national de la santé et de la recherche médicale. (Distinction).
  • (2000) FRM Postdoctoral Fellowship. Fonds de la recherche médicale. (Distinction).

Financement

(Completed). Principal Applicant. Gene expression in programmed cell death. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery grant. 250000 $ (2019-2024).

Grant. (Awarded). Co-applicant. Exploring the role of the circadian clock in regulating HIV replication and viral reservoir reactivation in Th17 cells. Canadian Institutes of Health Research (CIHR). Project grant. 772650 $ (2017-2022).

Publications

Articles de revue

  • Aurélie Delannoy* Mikaël Poirier* Brendan Bell. (2019). Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies. Viruses, 11(3), doi: 10.3390/v110302. (Published).
  • Delannoy A*, Wilhelm E*, Eilebrecht S, Milena Alvarado Cuevas E*, Benecke AG Bell B. (2018). BIM and NOXA are mitochondrial effectors of TAF6delta-driven apoptosis. Cell Death and Disease, 9(70), 1 - 15. (Published).
  • Tietjen I, Williams DE, Read S, Kuang X, Mwimanzi P, Wilhelm E*, Markle T, Kinloch NN, Naphen CN, Tenney K, Mesplède T, Wainberg MA, Crews P, Bell B, Andersen RJ, Brumme ZL, Brockman MA. (2018). Inhibition of NF-kappaB-dependent HIV-1 replication by the marine natural product bengamide A. Antiviral Res, 152, 94-103. (Published).
  • Wilhelm, E. Poirier, M. Bédard, M. Lavigne, P. Hunter, C. L. Bell, B. (2018). Mitotic deacetylase complex (MiDAC) recognizes the HIV core promoter to control Tat trans-activation and latency. submitted (PPATHOGENS-D-18-00781) to PLoS Pathogens,
  • Shkreta, L. Blanchette, M. Toutant, J. Wilhelm, E.* Bell, B. Story, B. Balachandran, A. Cochrane, A. Cheung, P. Harrigan, R. Grierson, D. Chabot, B. (2017). Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication. Nucleic Acids Res, 45(7), 4051-4067. (Published).
  • Conconi C, Bell B. (2017). Molecular biology: The long and short of a DNA-damage response. Nature, 545(7653), 165-166. (Published).
  • Shi T*, Wilhelm E, Bell B, Dumais N. (2017). Nf-kappab-Dependent Inhibition of HIV-1 Transcription by Withaferin A. HIV: Current Research, 2(1), 1 - 8. (Published).
  • Catherine Kamtchueng*, Marie-Éve Stébenne*, Aurélie Delannoy*, Emmanuelle Wilhelm*, Hélène Léger, Arndt G. Benecke, Brendan Bell. (2014). Alternative Splicing of TAF6: Downstream Transcriptome Impacts and Upstream RNA Splice Control Elements. PLOS ONE, 9(7), e102399 1-15. (Published).
  • Eilebrecht S , Wilhelm E* , Benecke BJ , Bell B , Benecke AG. (2013). HMGA1 directly interacts with TAR to modulate basal and Tat-dependent HIV transcription. RNA biology, 10(3), 436 - 444. (Published).
  • Wilhelm E* , Bell B. (2013). Selective recognition of viral promoters by host cell transcription complexes: challenges and opportunities to control latency. Current opinion in virology, Viral genomics, 380-386. (Published).
  • Wilhelm E , Doyle MC , Nzaramba I , Magdzinski A , Dumais N , Bell B. (2012). CTGC motifs within the HIV core promoter specify Tat-responsive pre-initiation complexes. Retrovirology, 9, doi:10.1186/1742-469. (Published).
  • Wilhelm E , Takacs C , Bell B. (2012). Probing endogenous RNA polymerase II pre-initiation complexes by electrophoretic mobility shift assay. Methods in molecular biology (Clifton, N.J.), 809, 63-74. (Published).
  • Wilhelm E , Kornete M , Targat B , Vigneault-Edwards J , Frontini M , Tora L , Benecke A , Bell B. (2010). TAF6delta orchestrates an apoptotic transcriptome profile and interacts functionally with p53. BMC molecular biology, 11, DOI: 10.1186/1471-21.

Chapitres de livre

  • L. Shkreta, B. Bell, T. Revil, J. P. Venables, P Prinos, S. Abou Elela and Benoit Chabot. (2013). Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing. Jane Y. Wu RNA and Cancer (41-94). Germany : Springer. (Published).

Autres contributions

Gestion d'évènements

  • Co-organiser. (2006-2015). Riboclub Opening Session. (Conference).

Activités de collaboration internationale

  • Collaborator of Dr. Arndt Benecke. (2007-2024). France. We maintain a longstanding and productive collaboration with Dr. Arndt Benecke and his team (Université Marie Curie, Paris). He is an expert in bioinformatics, genomics and gene expression and shares expertise with my group in genomic data analysis, statistical analysis and systems biology.
  • Collaborator of Dr. Jordan Meier. (2018-2021). United States. We have recently begun a collaboration with the laboratory of Dr. Jordan Meier at the NIH who is a recognized leader in the filed of modification of RNA by acetylcytidine. His expertise in detecting and characterization of these modifications is helpful for our new work on the role of RNA modification in HIV latency.
  • Collaborator of Dr. Ferenc Müller. (2010-2018). United Kingdom. We collaborate with Dr. Ferenc Müller (University of Birmingham) who is an expert in zebrafish development and in particular the role of TFIID and the TAFs in development. We have shown that TAF6delta is conserved in the zebrafish model. We are working to use CRISPR technology to specifically manipulate TAF6 isoform expression in vivo to define TAF6delta function in normal development and stress conditions.
  • Collaborator of Dr. Christie Hunter. (2011-2016). United States. Dr. Hunter is director of proteomics applications at AB SCIEX. She recently won the 2013 Science and Technology Award from the The Human Proteome Organization (HUPO). She has identified exciting new proteins that we have validated in cellulo as novel transcription factors controlling RNA polymerase II core promoter specificity.

Présentations

  • (2019). A return to core values: Identification of a new host cell transcription complex that controls HIV latency. Department of Biochemistry, Microbiology & Immunology (BMI) seminar series. Saskatoon, Canada.
  • (2018). A novel target for the block & lock HIV remission/cure strategy. Néoméd/GlaxoSmithKline (GSK) Discovery Fund competition. Canada.
  • Emmanuelle Wilhelm, Mikaël Poirier, Aurélie Delannoy, Pierre Lavigne, Brendan Bell. (2018). HIV latency is controlled by a novel histone deacetylase complex. CSV2018: The 2nd Symposium of the Canadian Society for Virology. Halifax, Canada.
  • Poirier M, Wilhelm E, Lavigne P, BellB. (2018). Pre-initiation complex dynamics and HIV latency. Riboclub Annual meeting. Orford, Canada.
  • (2018). Towards an end to HIV/AIDS: awaken a monster or bury it alive?. Seminar in the Department of Microbiology and Immunology, Dalhousie University. Halifax, Canada.
  • (2017). Contrôle de la latence dans la lutte contre le VIH: un nouveau complex HDAC. Journées Québécoise VIH. Montreal, Canada.
  • Aurélie Delannoy, Edith Milena Alvarado Cuevas, Emmanuelle Wilhelm. (2017). La voie TAF6delta: une question de vie ou de mort. Congrès de Biologie Médicale de l'université du Québec à Trois-Rivières. Trois Rivières, Canada.
  • (2017). New molecular keys to control HIV transcription and latency. CHUM. Montreal, Canada.
  • Poirier M, Wilhelm E, Lavigne P, Bell B. (2017). PICH-37 a cornerstone in HIV latency. Riboclub Annual meeting. Orford, Canada.
  • ?Poirier M, Wilhelm E, Lavigne P, Bell B. (2017). PICH-37 a cornerstone in HIV latency. CanCURE annual meeting. Montreal, Canada.
  • Poirier M, Wilhelm E, Bédard M, Lavigne P, Bell B. (2017). Une clé de la latence du VIH? Un nouveau complexe cellulaire qui régule la transcription en se liant le promoteur viral. Association francophone pour le savoir (ACFAS). Montreal, Canada.
  • Poirier M, Wilhelm E, Bédard M, Lavigne P, Bell B. (2017). Une clé de la latence du VIH? Un nouveau complexe cellulaire qui régule la transcription en se liant le promoteur viral. Protéomus annual meeting. Sherbrooke, Canada.
  • (2016). Identification of a new HDAC complex that controls HIV latency and contains potential targets for cure strategies. CanCURE annual meeting. Montreal, Canada.
  • Delannoy A A, Kirady C, Allaire J, Perreault N , Bell B. (2016). Surexpression paradoxale de Taf6? dans le cancer. Symposium de l’axe de recherche sur le Cancer de la FMSS. Sherbrooke, Canada.
  • Alvarado Cueva, EM, Wilhelm E, Bell B. (2015). Crosstalk between the TAF6delta and Notch pathways. The Notch Meeting IX. Athens, Greece.
  • Emmanuelle Wilhelm, Taharima Habib, Joannie Saint-Germain, Mikaël Bédard, Pierre Lavigne, Christie Hunter, Brendan Bell. (2014). Host cell pre-initiation complex of HIV (PICH) proteins: novel targets to control latency?. CanCURE Annual Scientific Retreat 2014. Canada.
  • Delannoy A, Léger H, Wilhelm E, Benecke A, Bell B. (2014). Implication de la voie mitochondriale dans l’apoptose induite par TAF6delta. Symposium de l’axe de recherche sur le Cancer de la FMSS. Sherbrooke, Canada.
  • Delannoy A, Léger H, Wilhelm E, Benecke A, Bell B. (2014). Implication de la voie mitochondriale dans l’apoptose induite par TAF6delta. Journée Phare de l’Institut de Pharmacologie de Sherbrooke. Orford, Canada.
  • Emmanuelle Wilhelm, Christie Hunter and Brendan Bell. (2013). Identification of novel host proteins controlling HIV gene expression. Riboclub opening session. Orford, Canada.
  • Emmanuelle Wilhelm, Marie-Christine Doyle, Nancy Dumais, Brendan Bell. (2011). Identification of Tat-responsive pre-initiation complexes (PICHs) at the HIV-1 core promoter. AIDS 2010 : XVIII international AIDS conference. Vienna, Austria.
  • Emmanuelle Wilhelm, Marie-Christine Doyle, Nancy Dumais, Brendan Bell. (2011). Vers le fondement de la latence du VIH. Axe des maladies infectieuses de l'Université de Sherbrooke. Sherbrooke, Canada.
  • (2010). Getting to the core of HIV latency: Identification of Tat-response pre-initiation complexes. Invited speaker at Institut Pasteur. Paris, France.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.